



The American Psychopathological Association (APPA) is devoted to the scientific investigation of disordered behavior and its biological and psychosocial substrates (<https://www.appassn.org/>). Each year, APPA sponsors a conference in New York City in March on a topic relevant to research on psychopathology. This year's topic is *Substance Use, Substance Use Disorders*. The meeting will be March 4-7, 2020 at the Times Square Crowne Plaza Hotel, Manhattan. Leading investigators from the U.S. and abroad will present original papers, with substantial time for questions and discussion by all. Additional activities are planned for early-career investigators. Below is the 2020 conference program. Activities highlighting junior scientists are shown in blue.

Conference registration will open in Fall, 2019 (see <https://www.appassn.org/> for updates). However, we wish to announce now a new early-registration discounted group rate for junior scientists. If 15 or more students, fellows and/or trainees register from the same program, institution or organization, their registration rate will be \$200 per person. For information, Deborah Hasin, Ph.D. at dsh2@cumc.columbia.edu or Deborah.hasin@gmail.com.

| 2020 APPA CONFERENCE PROGRAM: "SUBSTANCE USE, SUSTANCE USE DISORDERS" <i>Times Square Crowne Plaza Hotel, New York, New York</i> | |
|--|---|
| Wednesday, March 4, 2020 | |
| 12:00 - 5:00 | <i>Pre- & post-doctoral fellow/faculty workshop, fellow presentations</i> |
| 5:00 - 6:30 | <i>Workshop reception for fellows, faculty and other APPA members</i> |
| Thursday, March 5, 2020 | |
| 9:00-10:30 | Session 1: The view from National Institutes of Health |
| Chair: Deborah Hasin, PhD, Professor of Epidemiology; Columbia University (see bio sketch) | |
| The view from NIAAA | George Koob, PhD, NIAAA Director |
| The view from NIDA | Nora Volkow, MD, NIDA Director |
| | Discussion |
| 10:45 – 12:30 | Session 2: Policy |
| Chair/discussant: Silvia Martins, MD, PhD, Associate Professor of Epidemiology, Columbia University | |
| How can we reverse the tide of the opioid overdose epidemic? Evidence on the impact of policy solutions | Magdalena Cerdá, PhD, Assoc Professor; Director, Center for Opioid Epidemiology and Policy, New York University |
| The evolution of marijuana policy and how it has shaped marijuana markets | Rosalie Pacula, PhD, Professor and Chair, School of Public Policy, University of Southern California |
| Recent developments and dynamics between opioid-related harms and medical cannabis use in Canada | Benedikt Fischer, PhD, Professor, University of Toronto |
| | Discussion |
| | 3 junior scientist poster awardees: brief oral presentations |
| 1:30 – 3:00 | Session 3: Epidemiology |
| Chair/discussant: Charles Branas, Ph.D., Chair, Department of Epidemiology, Mailman School of Public Health, Columbia University | |
| Age, period, and cohort effects in substance use and mental health in the 21 st century | Katherine Keyes, PhD, Assoc Professor of Epidemiology, Co-Director, Psychiatric Epi Training Program, Columbia University |
| Breaking the intergenerational cycle of adversity: Substance abuse in the Boricua Youth Study | Christiane Duarte, PhD, Lambert Professor of Psychiatry; Director, Child Mental Health Disparities Group, Columbia University |
| Racial inequity in psychiatric and substance use disorders among African-Americans | Debra Furr-Holden, PhD, Mott Endowed Professor; Director, Flint Center for Health Equity Solutions, Michigan State University |
| | Discussion |
| 3:15 – 5:30 | Session 4: Neurofunctioning and genetics |
| Chair/discussant: Diana Martinez, M.D., Professor, Columbia University Department of Psychiatry | |
| Glutamate and the neurobiology of human alcoholism | John Krystal, M.D. Chair, Yale University Department of Psychiatry |
| Gender, stress, & substance use disorders | Rajita Sinha, PhD, Foundations Fund Professor; Director, Yale Interdisciplinary Stress Center, Yale University Department of Psychiatry |
| Genetics of substance disorders: Million Veteran Sample | Joel Gelernter, MD, Foundations Fund Professor; Director, Division of Human Genetics, Yale University Department of Psychiatry |
| Adolescent Brain & Cognitive Development (ABCD) study | Sandra Brown, PhD, Distinguished Professor of Psychology and Psychiatry; Vice Chancellor for Research, UCSD |
| | Discussion |

| | |
|--|---|
| 5:30 – 7:30 | Thursday Evening, March 5, 2020 Poster Session |
| Friday, March 6, 2020 | |
| 8:00 – 9:00 | Junior Investigator Breakfast Roundtable |
| 9:00 – 12:50 | Session 5: Measurement: diagnosis, outcomes |
| Chair/discussant: Eric Strain, MD, Professor and Executive Vice Chair for Psychiatry, Johns Hopkins Bayview Medical Center | |
| Presentation of Zubin award | Bridget Grant, PhD, PhD, Former Director, NIAAA Lab of Epidemiology |
| Substance use disorder nomenclature: DSM-5, ICD-11 | Wilson Compton, MD, Deputy Director, NIDA |
| Meaningful clinical trial endpoints | Stephanie O'Malley, PhD, Professor of Psychiatry; Director, Substance Abuse Research Division, Yale University |
| 9:55 – 10:10 | Discussion |
| | Presentation of Hoch award: Deborah Hasin, Ph.D. |
| 10:30-12:00 | Session 6: Exposure consequences I |
| Chair/discussant: Edward Nunes, M.D. Professor of Psychiatry, Columbia University; NIDA National Advisory Council member | |
| Cannabis and psychosis | Robin Murray, MD, Professor of Psychiatry (and former Dean), Institute of Psychiatry, Kings College |
| Substance use, overdose and suicide | Amy Bohnert, PhD Assoc Professor; Co-director, Mental Health Innovation, Services and Outcomes Program, University of Michigan |
| Predicting suicide among persons with substance use disorders in the population of Denmark | Jaimie Gradus PhD, Assoc Professor, Epidemiology/Psychiatry, Boston U |
| | Discussion |
| 12:00 – 1:00 | APPA annual business conference |
| 2:00 – 5:00 | Session 7: Exposure consequences II |
| Chair/discussant: Alan Budney, Ph.D., Professor, Dartmouth College | |
| Linking maternal risk traits to specific child diagnoses in Fetal Alcohol Spectrum Disorders (FASD)." | Philip May, PhD, Professor, Global Public Health, U North Carolina |
| Alcohol stimulating and sedating effects | Andrea King, PhD, Professor of Psychiatry, Director, Addiction Research Laboratory, University of Chicago |
| The risks and benefits of Naloxone prescribing to drug users: a randomized, controlled trial | Sandra Comer, PhD, Professor of Psychiatry; Director, Opioid Laboratory, Columbia University |
| Cannabis use disorder: current perspectives. | Margaret Haney, PhD, Professor of Psychiatry, Director, Cannabis Research Laboratory, Columbia University |
| | Discussion |
| Hoch award presentation | Mark Olfson, MD, Professor of Psychiatry, Columbia U; Co-Director, AHRQ Center for Education & Research on Mental Health Therapeutics |
| | Discussion |
| Saturday, March 7, 2020 | |
| 9:00 – 11:50 | Session 8: Evidence-based treatments and their dissemination |
| Chair/discussant: John Rotrosen, MD, Professor, Department of Psychiatry, New York University | |
| 9:00 – 9:05 | Robins-Guze award: TBD |
| Pharmacotherapy and pharmacogenetics of alcohol use disorder. | Henry Kranzler, MD, Professor of Psychiatry; Director, Center for Studies of Addiction, University of Pennsylvania |
| Pharmacological treatment, opioids | Joshua Lee, MD, Associate Professor; Director, ABAM fellowship in Addiction Medicine, New York University |
| 10-15- 10:30 | Discussion |
| Behavioral treatments for substance use disorders | Katherine Carroll, PhD, Kent Professor of Psychiatry; Director, Psychosocial Research on Addictions, Yale University |
| Screening & Dissemination | Richard Saitz, MD, Professor and Chair, Community Health Services, Boston University School of Public Health |
| 11:35 – 11:50 | Discussion |